Developer of a nanoparticle-based delivery platform intended to genetically engineer cells inside patients to create scalable, affordable, and potent cell and gene therapies. The company's platform provides a nanoparticle system that targets T-cells and delivers a chimeric antigen receptor (CAR) gene to turn them into tumour-killing CAR-T cells, enabling doctors to modify many different cell types, such as stem cells, neurons, and heart cells, addressing many indications for patients.